KRAS-Mutant Pancreatic CancerPhase 1NCT07671339
ELI-002 7P + mFOLFIRINOX ± Tislelizumab
ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
IExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
What the film says
Pancreatic cancer is usually found late, and nine in ten tumors run on one mutant gene, KRAS. For its commonest form, G12D, treatments are only now emerging.
The idea: instead of a drug, send instructions to switch the gene off.
Cells trade tiny packets called exosomes. In the lab, exosomes from donor stem cells are loaded with a short piece of RNA built to silence KRAS G12D. Infused into a vein, a surface tag tells the body's cleanup cells to leave them alone, and they collect in tumors. In mice, they slowed pancreatic tumors and lengthened survival.
This trial, at MD Anderson with Brandon Smaglo, gives them to people whose cancer carries G12D and has spread. First question: safety. Public record; not medical advice.
Sources behind this film
Waters AM. Cold Spring Harb Perspect Med, 2018
Usually found late; ~9 in 10 pancreatic cancers carry a KRAS mutation; G12D the commonest
G12D treatments only now emerging; Exosomes from donor stem cells loaded with siRNA against KRAS G12D; CD47 tag avoids clearance; accumulate in tumors; slowed tumors and lengthened survival in mice; People whose cancer carries G12D and has spread; safety first; MD Anderson with Brandon Smaglo
Kamerkar S. Nature, 2017
Exosomes from donor stem cells loaded with siRNA against KRAS G12D; CD47 tag avoids clearance; accumulate in tumors; slowed tumors and lengthened survival in mice
The drug
PRIMARY OBJECTIVES: I. To identify the maximum tolerated dose (MTD) of mesenchymal stem cell (MSC)-derived exosomes loaded with small interference RNA (siRNA) against KrasG12D (iExosomes) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients with KrasG12D mutation. II. To identify the dose-limiting toxicities (DLT) of mesenchymal stem cell (MSC)-derived exosomes loaded with siRNA against KrasG12D (iExosomes) in metastatic PDAC patients with KrasG12D mutation.
SECONDARY OBJECTIVES: I. Evaluate the pharmacokinetic profile of iExosomes. II. Assess the overall response rate of iExosomes in the chosen patient population. III. Assess the disease control rate (partial response + stable disease) with therapy. IV. Determine median progression-free survival (PFS) with this treatment. V. Determine the median overall survival (OS) with this treatment. EXPLORATORY OBJECTIVES: I.
The study
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.